CytomX Therapeutics to Present at Upcoming March Investor Conferences
28 Februar 2023 - 10:05PM
CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of
conditionally activated, localized biologics, today announced that
Sean McCarthy, D.Phil., chief executive officer and chairman, will
participate in the following investor conferences in March.
Cowen 43rd Annual Health Care Conference Date:
Tuesday, March 7, 2023Panel Discussion: 9:10 a.m. ETLocation:
Boston, MA
Barclays Global Healthcare Conference Date:
Tuesday, March 14, 2023Fireside Chat: 4:05 p.m. ETLocation: Miami,
FL
Live webcasts of the Cowen panel discussion and Barclays
fireside chat will be available on the Events and Presentations
page of CytomX’s website at www.cytomx.com. In addition, management
will be available for one-on-one meetings with investors who are
registered to attend the conferences.
About CytomX TherapeuticsCytomX is a
clinical-stage, oncology-focused biopharmaceutical company
dedicated to destroying cancer differently. By pioneering a novel
class of conditionally activated biologics, powered by its Probody®
technology platform, CytomX’s goal is to transcend the limits of
current cancer treatments. CytomX’s robust and differentiated
pipeline comprises five therapeutic candidates across multiple
treatment modalities including antibody-drug conjugates (“ADCs”),
T-cell engaging bispecific antibodies (“TCBs”), and immune
modulators such as cytokines and checkpoint inhibitors (“CPIs”).
CX-2029 is an investigational conditionally activated antibody-drug
conjugate (ADC) directed toward CD71 and is being developed in
collaboration with AbbVie. CytomX’s clinical pipeline also includes
cancer immunotherapeutic candidates against validated targets such
as the CTLA-4-targeting Probody therapeutic BMS-986288, partnered
with Bristol Myers Squibb, as well as CX-904, a conditionally
activated T-cell-engaging bispecific antibody targeting the
epidermal growth factor receptor (EGFR) on tumor cells and the CD3
receptor on T cells, which is partnered with Amgen. In addition,
CytomX has a diverse preclinical portfolio of wholly-owned assets
including CX-801, an interferon alpha-2b Probody cytokine that has
broad potential applicability in traditionally immuno-oncology
sensitive as well as insensitive (cold) tumors and CX-2051, a
conditionally activated ADC directed toward EpCAM, with potential
applicability across multiple EpCAM-expressing epithelial cancers.
CytomX has also established strategic collaborations with multiple
leaders in oncology, including AbbVie, Amgen, Astellas, Bristol
Myers Squibb, Regeneron and Moderna. For more information about
CytomX and how it is working to make conditionally activated
treatments the new standard-of-care in the fight against cancer,
visit www.cytomx.com and follow us on LinkedIn and Twitter.
Probody is a U.S. registered trademark of CytomX Therapeutics,
Inc.
CytomX Contact:Chris OgdenSVP,
Finance and Accounting cogden@cytomx.com(317) 767-4764
Investor and Media
Contact:Stern Investor RelationsStephanie
Ascherstephanie.ascher@sternir.com212-362-1200
CytomX Therapeutics (NASDAQ:CTMX)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
CytomX Therapeutics (NASDAQ:CTMX)
Historical Stock Chart
Von Mai 2023 bis Mai 2024